BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Minnillo BJ, Tabayoyong W, Francis JJ, Maurice MJ, Zhu H, Kim S, Abouassaly R. Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival. Can Urol Assoc J 2017;11:E184-91. [PMID: 28503232 DOI: 10.5489/cuaj.4137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Esdaille AR, Abel EJ. Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy. Cancer 2021. [PMID: 34286855 DOI: 10.1002/cncr.33788] [Reference Citation Analysis]
2 Berg S, Cole AP, Fletcher SA, Pucheril D, Nabi J, Lipsitz SR, Chang SL, Sun M, Noldus J, Harshman LC, Choueiri TK, Trinh QD. Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urol Oncol 2018;36:400.e15-22. [PMID: 30274640 DOI: 10.1016/j.urolonc.2018.06.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Desai AS, Pham M, Weiner AB, Siddiqui MR, Driscoll C, Jain-Poster K, Ko OS, Vo A, Kundu SD. Medicaid Expansion Did not Improve Time to Treatment for Young Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2020;18:e386-90. [PMID: 32280026 DOI: 10.1016/j.clgc.2020.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zhao Z, Wu W, Duan X, Zeng G, Liu Y. The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site-specific metastases. PLoS One 2019;14:e0215861. [PMID: 31013336 DOI: 10.1371/journal.pone.0215861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]